For the assessment of tumor response to ALK inhibition in vivo, we employed immunocompromised nonobese diabetes/severe combined immunodeficiency animals, inoculated with SW48 (CMS1) cells and then randomized into two groups: vehicle control and CZB (50 mg/kg/day). Here, ALK is linked to diabetes mellitus.